Skip to content

Released Nov 13, 2024, after the close

10-Q filed Nov 13, 2024, 44 days after period end · 0001683168-24-007971

Q3 2024 · 10-Q
Revenue—
Net Income-$5.97MN/M vs Q3 2023N/M vs Q2 2024
EPS Diluted-$0.55N/M vs Q3 2023N/M vs Q2 2024
Operating Income-$5,392,903N/M
Operating Cash Flowderived-$9,149,013N/M

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

MetricQ3 2024Q3 2023
Net Income-$5.97M-$6.34M
EPS Diluted-$0.55-$4.31

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Actuate Therapeutics, Inc. · CIK 1652935 · Engraved from SEC EDGAR